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Increased activation of the hypoxia-inducible
factor pathway in varicose veins
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Alun H. Davies, DM, FRCS,a London, United Kingdom
Background: Venous hypoxia has been postulated to contribute to varicose vein (VV) formation. Direct measurements of
vein wall oxygen tension have previously demonstrated that the average minimum oxygen tensions were significantly
lower in VVs compared with non-varicose veins (NVVs). Hypoxia-inducible factors (HIFs) are nuclear transcriptional
factors that regulate the expression of several genes of oxygen homeostasis. This study aimed to investigate if hypoxia was
associated with VVs by assessing the expression of HIF-1, HIF-2, HIF target genes, and upstream HIF regulatory
enzymes in VVs and NVVs, and their regulation by hypoxia.
Methods: VVs andNVVswere surgically retrieved and immediately snap-frozen or used for organ culture preparation. The relative
expression of HIF-1, HIF-2, HIF target genes, andHIF regulatory enzymes in VVs andNVVs was analyzed with quantitative
polymerase chain reaction (Q-PCR) andWestern blot. VV andNVVorgan ex vivo cultureswere exposed to 16 hours of normoxia,
hypoxia (oxygen tension1%), or the hypoxiamimetic dimethyloxallyl glycine (DMOG)1mM in normoxia. The vein organ cultures
were then analyzed for HIF-1, HIF-2, and their target gene expression with Q-PCR andWestern blot.
Results:HIF-1 andHIF-2mRNAwere significantly upregulated inVVs comparedwithNVVs (89.8 18.6 vs 10.4 7.2 and
384.9 209.4 vs 8.1 4.2, respectively).HIF target genemRNAexpressionwas also significantly elevated inVVs comparedwith
NVVs, namely glucose transporter-1 (GLUT-1; 8.7  2.1 vs 1.0  0.3), carbonic anhydrase-9 (CA9; 8.5  2.1 vs 2.8  1.2),
vascular endothelial growth factor (VEGF;7.52.1 vs0.90.2), andBCL2/adenovirusE1B19-kDaprotein-interactingprotein
3(BNIP-3;4.50.7vs1.40.3).TheupregulationofHIF-1,HIF-2, andHIFtargetgenes inVVswasalso reflectedatprotein
level. Of theHIF regulatory enzymes, the expression of prolyl-hydroxylase domain (PHD)-2 and PHD-3was found to be elevated
in VVs compared with NVVs. Exposure of VV and NVV organ cultures to hypoxia or DMOG was associated with increases in
HIF-1 andHIF-2 protein andHIF target gene expression compared with normoxia only.
Conclusions: The study concluded, we believe for the first time, an increased activation of theHIF pathway, with upregulation
of the expression ofHIF-1 andHIF-2 transcription factors, andHIF target genes, in VVs compared withNVVs. Exposure
of VVs and NVVs to hypoxic conditions was associated with increased expression of HIF-1 and HIF-2 protein and HIF
target genes. The data suggest that the HIF pathway may be associated with several pathophysiologic changes in the VVwall,
and that hypoxia may be a feature contributing to VV pathogenesis. (J Vasc Surg 2012;55:1427-39.)
Clinical Relevance:Varicose veins (VVs) cause debilitating symptoms, includingpain, skin changes, andulceration to patients.
Despite the burden, the pathophysiology of VVs remains incompletely understood. Vein wall changes are now thought to be
the primary events of VV formation. Understanding the upstream regulation of these changes may help to identify new
therapeutic targets for VVs. This study examined hypoxia as a potential factor associatedwithVVwall changes by assessing the
hypoxia-inducible factor (HIF) pathway in VVs. The results demonstrate an increased activation of the HIF pathway in VVs
which could be regulated by hypoxia, suggesting it as an attractive therapeutic target for the disease.
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doi:10.1016/j.jvs.2011.10.111Varicose veins (VVs) affect about one-third of the adult
estern population.1 Patients with VVs may experience
ain, ankle edema, itch, eczema, lipodermatosclerosis, and
lceration. Treatment of complications of VVs has been
stimated to cost 1% to 3% of the health care spending of
any developed countries.1,2 However, despite this signif-
cant burden, the mechanism of VV formation remains
nclear. Increasing evidence supports vein wall alterations
nd dilation as the primary events causing VV formation,
nd suggests that valvular dysfunction may be an epiphe-
omenon of vein wall changes. Structural and biochemical
hanges that have been reported in the VV wall include
ntimal hyperplasia, dysregulated apoptosis, smooth muscle
ell proliferation, abnormal glucose metabolism, altered
ngiogenesis, changes in collagen and elastin content, and
mbalances of matrix metalloproteases and their tissue in-
ibitors.1,3
Venous hypoxia secondary to blood stasis in patients
ith chronic venous disease has been postulated to contributeo VV wall changes.1,4 Vein wall oxygenation is achieved
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May 20121428 Lim et alby diffusion of oxygen from blood in the lumen as well as from
the vasa vasorum. In patients with chronic venous disease,
blood stasis is thought to cause venous hypoxia through the
reduction of luminal blood oxygen replenishment rate in
comparison to normal venous flow (endoluminal hypoxia),
and the distension of the vein secondary to increased luminal
hydrostatic pressure causing compression of vasa vasorum
(medial hypoxia).4 Although findings from studies comparing
the oxygen content in blood from VVs and non-varicose veins
(NVVs) have been inconclusive, direct measurement of vein
wall oxygen tension by Taccoen et al5 demonstrated that the
average minimum oxygen tensions were significantly lower in
VVs compared to NVVs, suggesting that VVs may be associ-
ated with hypoxia.4
Hypoxia-inducible factors (HIFs) are nuclear tran-
scriptional factors that regulate the transcription of
genes which mediate cellular and tissue homeostatic
responses to altered oxygenation. HIF is a heterodimeric
transcription factor composed of two subunits, HIF-,
which is oxygen-regulated, and HIF-, which is expressed
constitutively in the nucleus. Three HIF- isotypes (HIF-
1, HIF-2, and HIF-3) have been identified. Whereas
HIF-1 and HIF-2 share similar gene sequence, protein
structure, biochemical properties, and regulatory pathways,
they have different embryonic deletion phenotypes, tissue
distribution, and biological effects.6-9 The regulation and
function of HIF-3 is less clear, although it may be in-
volved in the negative regulation of HIF-induced gene
transcription.9 The expression of HIF- in many tissues
increases exponentially as oxygen concentration declines.10
Both the stability and transcriptional activity of HIF- are
negatively regulated by oxygen-dependent hydroxylation.
Under normoxia, HIF- protein subunits are hydroxylated
on proline residues by HIF-prolyl hydroxylase domain
(PHD) enzymes, namely PHD-1, PHD-2, and PHD-3.6,11
The PHDs require oxygen and -ketoglutarate as cosub-
strates to catalyze a dioxygenase reaction in which one
oxygen atom is inserted into -ketoglutarate to form suc-
cinate and CO2.
12 Hydroxylation of a proline residue of
HIF- is essential for the binding of von Hippel–Lindau
(VHL) protein, which interacts with Elongin C, facilitating
the recruitment of an ubiquitin ligase complex. Ubiquiti-
nation of HIF- marks it for proteosomal degradation.6,11
Besides prolyl hydroxylation, HIF-1 is also subjected to
hydroxylation of asparagine residue 803 by factor-inhibiting
HIF-1 (FIH-1) during normoxia.13 Asparaginyl hydroxyla-
tion negatively regulates HIF- transactivation activity by
blocking the interaction of the transactivation domain with
the coactivator p300.11 In hypoxia, both oxygen-dependent
hydroxylation activity of PHD enzymes and FIH-1 are sup-
pressed.14,15 HIF- dimerizes with HIF- in the nucleus and
binds the hypoxia-responsive element of target genes activat-
ing their transcription.6,11
Genes regulated by HIF are involved in many cellular
functions, including angiogenesis, glucose metabolism, pH
regulation, matrix metabolism, cell cycle and apoptosis,
erythropoiesis, and vascular tone.9,16 Interestingly, many Lf these processes are also altered in VVs compared to
VVs, including matrix metabolism, vascular tone, cell
ycle and apoptosis, and glucose metabolism.1,3 Therefore,
he aims of this study were to assess the HIF pathway by
easuring the expression of HIF-1, HIF-2, HIF target
enes, namely carbonic anhydrase-9 (CA9), glucose trans-
orter-1 (GLUT-1), vascular endothelial growth factor
VEGF), which is a key angiogenic factor, and BCL2/
denovirus E1B 19-kDa protein-interacting protein 3
BNIP-3), as well as HIF regulatory enzymes (PHDs and
IH-1) in VVs and NVVs obtained immediately after sur-
ery. Because oxygen is the most well-known and studied
actor that regulates the HIF pathway, the study also aimed
o investigate if NVVs and VVs were able to activate the
IF pathway through the oxygen-dependent regulation
athway under hypoxic stress using a vein organ culture
odel to examine the potential role of reduced oxygen
ension in promoting VV development.
ETHODS
Patient recruitment and tissue collection. Ethical
pproval for the study was obtained from the Riverside Re-
earch Ethics Committee (RREC3092), London, United
ingdom.
Primary VVs were retrieved from patients who under-
ent open surgery or endovenous treatment with phlebec-
omies for VVs. The VVs used were refluxing, hence dis-
ased truncal veins or their tributaries in any location of the
uperficial venous system of the leg. All patients with VVs
ere scanned with duplex ultrasonography while in the
tanding position and refluxing veins were marked by vas-
ular scientists preoperatively. Reflux was defined as retro-
rade flow lasting for more than 0.5 seconds. NVVs were
btained from patients with no history of VVs and under-
oing the following surgery: arterial bypass with vein graft
great saphenous vein [GSV]), arteriovenous fistula forma-
ion (cephalic vein), open inguinal hernia repair (subcuta-
eous groin vein or inferior epigastric vein), limb amputa-
ion (saphenous vein), and carotid endarterectomy (facial
nd external jugular vein). The NVVs were not routinely
canned for reflux with duplex ultrasonography. Patients
ith a history of secondary VVs, including deep venous
hrombosis and congenital VVs, connective tissue disease,
asculitis, and rheumatoid arthritis were excluded from the
tudy. The demographic data, medical history, type of vein,
nd the CEAP classification of patients recruited are pre-
ented in Tables I and II. The tissues were snap-frozen in
iquid nitrogen in the operating theater and stored at -80°C
or polymerase chain reaction (PCR) and Western blot
nalysis. Tissues collected for vein organ culture prepara-
ion were transported in Dulbecco Modified Eagle’s Me-
ium (DMEM; PAA Laboratories GmbH, Pasching, Aus-
ria) to the laboratory. Vein organ cultures were prepared
ithin 1 hour from the time of retrieval from the patient.
Reverse transcription and polymerase chain reaction.
or RNA analysis, total RNA from whole VV and NVV
issues was isolated using RNA-Bee (AMS-Biotechnology
td, Oxon, UK). Total RNA (0.5 g) was reverse tran-
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Volume 55, Number 5 Lim et al 1429scribed using Moloney Murine Leukemia Virus Reverse
Transcriptase (Promega, Southampton, UK) and analyzed
by real-time quantitative-PCR (Q-PCR) using a thermocy-
cler Rotor-Gene 6000 Multiplexing System (Corbett Re-
search, Cambridge, UK). The primers used are shown in
the Supplemental Table (online only). The mRNA expres-
sion was calculated using the 2-Ct method, in relation to
(1) a NVV specimen when comparing the gene expres-
sion between VV and NVV, or (2) the corresponding
vein organ culture exposed to normoxia when assessing
the effects of hypoxia and dimethyloxallyl glycine
(DMOG) on VV and NVV organ cultures. The relative
mRNA expression was normalized to 18S RNA as the
housekeeping gene.
Western blot. Whole vein tissues were homogenized in
ice-cold 8M urea buffer containing 1/10 volume glycerol,
1/1000 volume 1M dithiothreitol, 1/100 volume 1M Tris
(pH 6.8), 1/20 volume of 20% sodium dodecyl sulfate (SDS),
1/200 volume 0.1M stock of phenylmethylsulfonyl fluoride,
1/100 volume complete mini EDTA-free protease inhibitor
cocktail 50 mM (Roche Applied Science, West Sussex, UK).
The homogenates were centrifuged at 13,000 revolutions per
minute for 5 minutes at 4°C. The total extracted protein
concentration was assayed using BCA Protein Assay Kit
Table I. Demographic data of patients whose veins were
used for analysis of HIF-1, HIF-2, HIF target genes,
and HIF regulatory enzyme mRNA and protein
expression with Q-PCR and Western blot
Non-varicose veins Varicose veins
Number of patients 11 20
Mean age (range)/year 67.4 (46-85) 48.9 (30-74)
Gender 8 males, 3 females 9 males, 11 females
Smoking 6 nonsmokers 11 nonsmokers
3 ex-smokers 2 ex-smokers
2 smokers 7 smokers
Medical history
Cardiac disease 3 0
Diabetes mellitus 4 1
Peripheral arterial
disease 9 0
Hypertension 8 3
Type of vein
Neck (facial and
external jugular) 5 0
Saphenous or
tributaries 4 20
Groin 1 0
Arm 1 0
Clinical CEAP
C0/1 11 0
C2 0 9
C3 0 6
C4a 0 3
C4b 0 0
C5 0 2
C6 0 0
HIF, Hypoxia-inducible factor; Q-PCR, quantitative polymerase chain re-
action.(Thermo Scientific, Rockford, Ill). Equal amounts of pro- sein extract (40 g in each well) were resolved by sodium
odecyl sulfate polyacrylamide gel electrophoresis (SDS-
AGE) and transferred onto polyvinylidene difluoride
embranes (Millipore, Billerica, Mass). Membranes
ere blocked with phosphate-buffered saline, containing
.1% Tween-20 (Sigma-Aldrich, Dorset, UK)/5% nonfat
ry milk and probed with the following primary antibodies:
ouse monoclonal anti-HIF-1 (1:250; BD Transduction
aboratories, Heidelberg, Germany), mouse monoclonal
nti-HIF-2 (1:250; Novus Biologicals, Littleton, Colo),
abbit polyclonal anti-CA9 (1:1000; Novus Biologicals),
abbit polyclonal anti-GLUT-1 (1:500; Alpha Diagnostic
nternational, San Antonio, Tex), rabbit polyclonal anti-
HD-1 (1:1000; Abcam, Cambridge, Mass), rabbit poly-
lonal anti-PHD-2 (1:1000; Abcam), mouse monoclonal
nti-PHD-3 (1:25; gift from Professor C.W. Pugh, Ox-
ord, UK), rabbit polyclonal anti-FIH-1 (1:1000; Novus
iologicals), and rabbit polyclonal antiextracellular signal-
egulated kinase-2 (ERK-2; 1:500; Santa Cruz Biotechnol-
gy, Santa Cruz, Calif). Bound antibody was detected with
ppropriate horseradish peroxidase conjugated secondary
ntibodies (DakoCytomation, Copenhagen, Denmark)
nd ECL Plus Western Blotting Detection System (GE
ealthcare, Buckinghamshire, UK). The ERK-2 was used
s the loading control in all the Western blot runs to ensure
qual loading of protein extract in the wells. ERK-2 has
reviously been used as Western blot loading control in
able II. Demographic data of patients whose veins
ere used for vein organ culture preparation
Non-varicose veins Varicose veins
umber of patients 6 6
ean age (range)/year 64.2 (45-72) 47.5 (33-63)
ender 5 males, 1 female 3 males, 3 females
moking 2 nonsmokers 3 nonsmokers
2 ex-smokers 1 ex-smoker
2 smokers 2 smokers
edical history
Cardiac disease 3 1
Diabetes mellitus 2 0
Peripheral arterial
disease 5 0
Hypertension 5 0
ype of vein
Neck (facial and
external jugular) 0 0
Saphenous or
tributaries 5 6
Groin 0 0
Arm 1 0
linical CEAP
C0/1 6 0
C2 0 0
C3 0 3
C4a 0 2
C4b 0 0
C5 0 1
C6 0 0tudies comparing VVs and NVVs.17
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were prepared based on a model previously described by
Soyombo et al18 with some modifications. Briefly, veins
were cut open longitudinally and transversely to expose the
endothelial surface and dissected into segments measuring
0.5 cm  0.5 cm. Each segment was then pinned out with
A1 minuten pins (Watkins and Doncaster, Kent, UK) at the
four corners with the endothelial surface uppermost, onto a
polyester mesh (Sericol Limited, Kent, UK) resting on
sylgard resin (Dow Corning, Seneffe, Belgium) in a glass
Petri dish (DURAN Group GmbH, Mainz, Germany).
The culture medium used was 5 mL of DMEM High
Glucose (4.5 g/L) with l-glutamine, and sodium pyruvate
(PAA Laboratories GmbH, Pasching, Austria) plus 100
unit/mL penicillin and 0.1 mg/mL streptomycin (PAA
Laboratories GmbH) plus 10% fetal bovine serum (Gibco,
Invitrogen Life Sciences, Paisley, UK). The viability of the
vein organ culture has previously been validated with cell
death assay by our department (data not shown). Similar to
the findings previously described by Soyombo et al,18 our
vein organ cultures remained viable after 7 days of culture.
Vein organ cultures were subjected to one of the fol-
lowing conditions: (1) normoxia (95% air with 5% CO2),
(2) DMOG (Frontier Scientific, Logan, Utah) 1 mM, and
(3) hypoxia (1% O ). DMOG is a nonspecific inhibitor of
HIF-1
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Fig 1. Hypoxia-inducible factor (HIF)-1 and HIF-2
mRNA expression of HIF-1 and HIF-2 in varicose
quantitative polymerase chain reaction (Q-PCR), and n
interquartile range) of mRNA expression relative to the
using 2-Ct method, in 11 varicose and five non-var
Mann-Whitney U test, respectively. * P  .05; ** P  .0
and non-varicose veins assessed using Western blot, wi
loading control.2
both prolyl and asparaginyl hydroxylases, thereby blocking the .ctivity of PHD and FIH-1. By inhibiting PHD and FIH-1,
MOG stabilizes and increases the activity of HIF-.19 After
6 hours, the organ cultures were immediately snap-frozen
n liquid nitrogen and stored at -80°C for Q-PCR and
estern blot analysis as described above.
Statistical analysis. Statistical analyses were performed
ith Graphpad Prism, version 5.00 (Graphpad Software, San
iego, Calif). Data represent mean  SEM or median and
nterquartile range as indicated. The data on gene expression
n VVs and NVVs were tested for normality by Kolmogorov-
mirnov test, and then by two-tailed unpaired t-test, or non-
arametric Mann-Whitney U test. The data on the effects of
ypoxia and DMOG on VVs and NVVs were analyzed with
ne-way analysis of variance (ANOVA) with Dunnett’s mul-
iple comparisons correction. A P value .05 was considered
tatistically significant.
ESULTS
Hypoxia-inducible factor-1 and hypoxia-inducible
actor-2 expression in varicose veins and non-varicose
eins. Q-PCR analysis demonstrated that HIF-1 mRNA
xpression was significantly upregulated in VVs compared
ith NVVs, with mean relative gene expression of 89.8 
8.6 (n  11) and 10.4  7.2 (n  5), respectively (P 
HIF-2
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non-varicose veins. Gene expression was assayed by
lized to 18S RNA. Data are median fold change (and
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veins, and were compared using unpaired t-test and
, Expression of HIF-1 and HIF-2 protein in varicose
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Volume 55, Number 5 Lim et al 1431also significantly higher in VVs than NVVs, with mean
relative gene expression of 384.9  209.4 and 8.1  4.2,
respectively (P  .008; Fig 1, A). Western blot analysis
showed increased immunoreactive bands at 	120 kDa
corresponding to HIF-1 and HIF-2 in VV (n  4)
compared with NVV (n  4) samples (Fig 1, B).
Hypoxia-inducible factor target gene expression in
varicose veins and non-varicose veins. The mRNA levels
BNIP-3
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Fig 2. Hypoxia-inducible factor (HIF) target gene expr
expression of HIF target genes, namely BCL2/adeno
carbonic anhydrase (CA)-9, glucose transporter-1 (GL
varicose and non-varicose veins. The mRNA was assaye
normalized to 18S RNA. Data are median (and interqua
expression of a non-varicose vein specimen, calculated us
The differences in gene expression between varicose an
(BNIP-3) or Mann-Whitney U test (CA9, GLUT-1, an
protein in varicose and non-varicose veins assessed us
(ERK)-2 shown as a loading control.of HIF target genes were significantly increased in VVs cn  20) compared with NVVs (n  10), namely glucose
ransporter GLUT-1 (8.7  2.1 vs 1.0  0.3; P  .001),
A9 (8.5  2.1 vs 2.8  1.2; P  .006), the angiogenic
actor VEGF (7.5  2.1 vs 0.9  0.2; P  .001), and
NIP-3 (4.5  0.7 vs 1.4  0.3; P  .004; Fig 2, A). The
xpression of one of the HIF target genes, CA9, was also
ssessed at the protein level. Using Western blot analysis,
A9 expression was found to be elevated in VVs (n  4)
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pression in varicose veins and non-varicose veins. The
mRNA expression of PHD-2 and PHD-3 was significantly
increased in VVs (n  11) compared with NVVs (n  5).
Expression of PHD-2 was equivalent to 5.6 1.1 in VVs vs
1.7 0.7 in NVVs (P .034), whereas PHD-3 expression
in VVs was 9.9 2.2 vs 2.4 1.2 in NVVs (P .047). No
significant difference in PHD-1 and FIH-1 mRNA expres-
sion was observed between VVs (n  11) and NVVs (n 
5): PHD-1, 3.2  0.8 vs 1.6  0.9 and FIH-1, 3.6  0.7
vs 4.4  2.2 (Fig 3, A). In Western blot analysis, bands
corresponding to PHD-2 and PHD-3 were more marked
in VVs (n  4) compared with NVVs (n  4). In contrast,
the intensity of protein bands corresponding to PHD-1 and
FIH-1 appeared similar between VVs (n  4) and NVVs
(n  4; Fig 3, B).
The effect of hypoxia on hypoxia-inducible
factor-1 and hypoxia-inducible factor-2 expression
in varicose veins and non-varicose veins. To further
analyze the potential role of hypoxia in inducing genes
relevant to VV pathogenesis, vein segments were cultured
ex vivo and exposed to hypoxia, or the hypoxia-mimetic
and PHD/FIH inhibitor DMOG. Exposure of NVV organ
cultures (n 6) to hypoxia or DMOG significantly reduced
HIF-1 mRNA (P  .05 and P  .001, respectively) but
not HIF-2 mRNA expression compared with those sub-
jected to normoxia only (Fig 4, A). Similarly, exposure of
VV organ cultures (n  6) to hypoxia or DMOG signifi-
cantly reduced HIF-1 (both P  .001) but not HIF-2
mRNA expression compared with those exposed to nor-
moxia only (Fig 4, A). Western blot analysis demonstrated
increased HIF-1 and HIF-2 protein in VV (n  4) and
NVV (n  4) organ cultures exposed to hypoxia and
DMOG compared with their respective untreated vein
organ cultures in normoxia (Fig 4, B).
The effects of hypoxia on hypoxia-inducible factor
target gene expression in varicose veins and non-
varicose veins. Exposure of NVV organ cultures to hyp-
oxia significantly increased the expression of all the HIF
target genes assessed (CA9, BNIP-3, PHD-2, PHD-3, and
GLUT-1) except VEGF compared with those subjected to
normoxia only (Fig 5, A). Although statistically not signif-
icant, a trend toward increased VEGF mRNA expression
was observed in NVV organ cultures exposed to hypoxia
compared with normoxia (Fig 5,A). Meanwhile, treatment
of NVV cultures with DMOG significantly increased the
expression of all the HIF target genes assessed (CA9,
BNIP-3, PHD-2, PHD-3, GLUT-1, and VEGF) com-
pared with those subjected to normoxia (Fig 5, A). Expo-
sure of VV organ cultures to hypoxia or DMOG signifi-
cantly increased the expression of all the HIF target genes
assessed (CA9, BNIP-3, PHD-2, PHD-3, GLUT-1, and
VEGF) compared with those subjected to normoxia only
(Fig 6, A). The effects of hypoxia and DMOG on the
expression of two HIF target genes in VVs and NVVs were
also assessed at the protein level with Western blot analysis.
The expression of GLUT-1 and PHD-3 was found to be
increased in NVV (Fig 5, B) and VV (Fig 6, B) organ eultures exposed to hypoxia or DMOG compared with
hose in normoxia only (n  4).
ISCUSSION
Venous hypoxia secondary to blood stasis in patients with
hronic venous disease has been postulated to contribute to
V wall changes.1,4 Although findings from studies compar-
ng the oxygen content in blood from VVs and NVVs have
een inconclusive, direct measurement of vein wall oxygen
ension by Taccoen et al5 demonstrated that the average
inimum oxygen tensions were significantly lower in the
edia of VVs compared with NVVs (7.9 vs 13.4 mm Hg;P
05), suggesting that VVs may be associated with medial
ypoxia.4 It is well described that cells and tissues which are
ssociated with hypoxia exhibit increased activation of the
IF pathway.14,15 Therefore, this study investigated the HIF
athway in VVs and NVVs, which would determine whether
ypoxia was a feature of VVs.
This study demonstrated increased activation of the HIF
athway in VVs compared with NVVs. The expression of
IF-1 and HIF-2was found to be significantly increased at
RNA and protein levels in VVs compared with NVVs. This
tudy also showed, we believe for the first time, that the
xpression of several well-known HIF target genes was signif-
cantly upregulated in VVs compared with NVVs, further
upporting the concept of increased activation of the HIF
athway in VVs. These HIF target genes are known to regu-
ate several cellular processes, including glucose metabolism
GLUT-1), apoptosis and cell survival (BNIP-3), pH regula-
ion (CA9), and angiogenesis (VEGF), all of which are known
o be altered in VVs compared with NVVs.1-3 These processes
re well-known cellular responses to hypoxia. For example,
ells respond to hypoxia by increasing their glucose uptake for
nergy production, upregulating angiogenesis to improve ox-
gen delivery, regulating their cellular pH to prevent acidosis
econdary to anaerobic respiration, and altering their survival/
poptosis. However, whether the upregulation of these genes
n the development of VVs is solely to protect the venous
issue from hypoxia or not remains to be proven. Individually,
he HIF target genes may also be regulated by different stimuli
hat are independent from the HIF pathway. However, when
ll or several of them are upregulated simultaneously, as dem-
nstrated in this study, increased activation of the HIF path-
ay is almost certainly involved. Therefore, our novel data
uggest that it is likely that the increased activation of the
IF pathway may contribute to the pathophysiologic
hanges of VV walls. Furthermore, this study also showed
hat both VV and NVV organ cultures increased the acti-
ation of the HIF pathway in vitro when exposed to hyp-
xia, a factor that has been previously postulated to con-
ribute to VV formation.
As discussed earlier, PHDs and FIH-1 negatively reg-
late the stabilization and transactivation activity of HIF-
hrough prolyl and asparaginyl-hydroxylation, respectively,
rocesses which do not occur in hypoxia due to the require-
ent of HIF hydroxylases for oxygen as a substrate. This
xplains our findings that increases in PHD-2 and PHD-3
xpression in vein organ cultures exposed to hypoxia or
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May 20121434 Lim et alDMOG did not downregulate the expression of HIF-1
and HIF-2 protein. In this study, we also assessed the
expression of the HIF regulatory enzymes (ie, PHDs and
FIH-1) in order to better understand the mechanism of
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HIF.11,20 The finding of increased PHD-2 and PHD-3
expression further supports the hypothesis that hypoxia and
the HIF pathway are active in VVs.
The mechanism of the regulation of the HIF pathway
by oxygen has been well reported in the literature in various
cells and tissues.6,10,14 The role of the HIF pathway in
contributing to the pathogenesis of several diseases related
to hypoxia, including some cancers, rheumatoid arthritis,
atherosclerosis, chronic anemia, and stroke, has also been
previously reported.10,15,21 However, we believe that this
study was the first to demonstrate in detail that the in-
creased activation of the HIF pathway may be associated
with several pathophysiologic changes in VVs, and thereby
that hypoxia and HIF may have a significant role in VV
disease. Before this study, little was known about the HIF
pathway in VVs, and there was only indirect evidence to
suggest the possibility of involvement of the HIF pathway
in VV pathophysiology. First, it has been reported that the
mean oxygen tension measured in vivo in the VV wall was
significantly lower than in NVVs, suggesting that VVs are
hypoxic.5 Second, patients with Chuvash polycythemia, an
inherited disorder of inappropriate increased HIF activity
due to a VHL gene mutation, were more likely to have VVs
than the general population.22 Third, it has been reported
that internal spermatic veins of patients with varicoceles, a
condition similar to VVs, expressed significantly more
HIF-1 than those of patients without the disease.23 Only
recently, Hossein-Ghaderian et al24 described HIF-1 ex-
pression in endothelial cells of the intima and vasa vasorum
of five of 20 VV specimens, but none of the 20 non-varicose
saphenous vein tissues using immunohistochemistry. Using
immunohistochemistry, we have also previously shown that
HIF-1 expression was localized to the endothelial lining
of VVs and NVVs, whereas HIF-2 and a representative
HIF target gene, CA9, were expressed in endothelial lining
and tunica media of both types of veins.25 However, the
HIF pathway in VVs and NVVs has never been studied in
detail. This study was the first to investigate the expression
of HIF-2, HIF target genes, HIF regulatory enzymes, and
their regulation by hypoxia in VVs and NVVs.
It is unclear at what stage of VV formation the HIF
pathway is activated. It is also unknown if activation of the
HIF pathway contributes to VV formation or if it is an
effect caused as a result of varicosity. Like many features of
VVs, the cause and effect relationship of the HIF pathway
and VVs may be difficult to ascertain, particularly whether it
contributes to a vicious cycle of disease progression. How-
ever, increased activation of the HIF pathway in VVs is a
significant finding because HIFs regulate approximately 1%
of human genes, including genes mediating oxygen ho-
meostasis.11 Many of the HIF target genes are involved in
functions that are known to alter the pathophysiologic
changes of the vein wall such as angiogenesis, matrix me-
tabolism, glucose metabolism, vascular tone, pH regula-
tion, cell cycle, and apoptosis.8,9,14,16 Therefore, regardless
of the stage at which the HIF pathway is affected during VV
formation, it is likely to contribute to many pathophysio- wogic changes in the VV wall, making it a potentially attrac-
ive therapeutic target in the disease. It is also unclear if the
egree of activation of the HIF pathway in VVs is associated
ith the severity of the disease or different CEAP groups;
n important question that needs to be addressed in future
tudies. There are many HIF modulating drugs, both
nhibitors and stabilizers, being developed and investi-
ated in various diseases, including cancers, rheumatoid
rthritis, and ischemic heart disease.26-28 Examples of
IF inhibitors include EZN-2968,29 sorafenib,30 and
chinomycin,31 whereas the most important group of
rugs that increases the expression of HIF are inhibitors
f PHD and FIH-1 such as DMOG, desferrioxamine,
nd 3,4-dihydroxybenzoate.26,27 FG-2216 and FG-
592 are two orally active PHD inhibitors being tested
n clinical trials for the treatment of anemia in patients
ith chronic kidney disease.10,32
Interestingly, despite the fact that our in vitro study
emonstrated that hypoxia downregulated the HIF-1
xpression in VV and NVV cultures, which is in agreement
ith most cell culture studies, the expression of HIF-1
RNA was found to be increased in snap-frozen VVs
ompared with NVVs, suggesting the contribution of other
actors in activating the HIF pathway, possibly through
ifferent mechanisms. Although the oxygen-dependent reg-
lation of HIF-1 and HIF-2, which is well described to
ccur at protein level, is well understood and consistent in
arious cell lines and tissues, the regulation of the HIF-1
RNA by hypoxia is complex and incompletely under-
tood.33 For example, it has been reported that several feed-
ack mechanisms may lead to alteration of the HIF-1 activity
nd adjustment of the cells to sense relative hypoxia with
ifferent ambient oxygen levels.33 Examples of feedback
echanisms for HIF-1 during sustained hypoxia include the
eneration of an antisense RNA to HIF-1 (aHIF),34 pro-
uction of CBP/p300-Interacting-Transactivator-with-ED-
ich-tail-2 (CITED-2) that can bind and block p300 recruit-
ent required for HIF-1 transcriptional activity,33 activation
f PHD-2 and PHD-3 transcription which negatively regulate
IF-1 expression,33 and induction of an HIF-3 isoform
hat acts as a dominant inhibitor of HIF-1.9
The vein organ cultures were exposed to hypoxia or
MOG for 16 hours to demonstrate the maximum activa-
ion of the HIF pathway. This duration of inhibition of
rolyl and asparaginyl hydroxylation resulted in marked
IF stabilization and activation leading to HIF target gene
ranscription to occur, while limiting the activation of the
eedback regulations of HIF-1 by sustained hypoxia. It
as previously been reported that 16 hours of exposure of
ell culture to 1% oxygen or DMOG show overall concor-
ance of patterns of gene expression, indicating the central
nvolvement of prolyl and asparaginyl hydroxylases in the
ranscriptome response to altered oxygen tension.19
One of the challenges often faced when studying VVs is
he selection of NVV controls. The anatomically matched
VV controls would be the superficial leg veins such as the
SV, often obtained from arterial bypass surgery during
hich this vein is harvested for grafting. However, patients
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cardiovascular-related comorbidities and are usually older
than those who undergo VV surgery. These cardiovascular-
related comorbidities and smoking may potentially alter the
oxidative stress and the ischemic state of the venous tissues.
However, excluding all patients with these comorbidities and
those who smoke would reduce the number of eligible con-
trols significantly. This would reduce the representation of our
findings to a very small and probably unrealistic group of
patients. Furthermore, this would also reduce our control
vein samples significantly. In this study, we used heteroge-
neous sources of NVVs, including neck veins, groin veins,
and arm veins, including several NVVs from patients who
were relatively young and with no cardiovascular-related
comorbidities (groin veins from inguinal hernia repair sur-
gery), while maintaining the anatomically matched super-
ficial leg veins as the predominant control NVV. Our
previous study that used similar heterogeneous sources of
NVV controls to study matrix metabolism of VVs demon-
strated little difference in the expression levels of matrix
metalloproteases and their inhibitors between these differ-
ent sources of NVVs, suggesting that they were suitable
alternative controls for VVs.35 To ensure that our NVVs of
heterogenous anatomic sources demonstrated little differ-
ence in this study, we performed a simple subgroup analysis
of the NVV group using unpaired t-test. We found that
there was no significant difference in the mRNA expression
of the HIF target genes (ie, CA9, BNIP-3, VEGF, and
GLUT-1) between the NVVs obtained from the leg (sa-
phenous, tributaries, and groin veins) and those not from
the leg (arm and neck).
In conclusion, this study demonstrated, we believe for
the first time, an increased activation of the HIF pathway,
with upregulation of the expression of HIF-1 and HIF-2
transcription factors, together with increased expression of
HIF target genes, including the expression of the HIF
regulating enzymes (PHD and FIH) in VVs compared with
NVVs. Exposure of VVs and NVVs to hypoxic conditions
was associated with increased expression of HIF-1 and
HIF-2 protein, and HIF target genes, suggesting that this
model can be used to further study the hypoxia/HIF
pathway in VVs using small molecule activators and inhib-
itors of HIF and will allow us to better understand HIF
regulation. Although this study did not confirm that hyp-
oxia causes VV formation, the data suggest that the HIF
pathway may contribute to or associate with several patho-
physiologic changes in the VV wall, and that hypoxia may
be a feature contributing to VV pathogenesis. Modulation
of the HIF pathway is therefore a potentially attractive
therapeutic target for pharmacologic treatment for VVs.
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Primer Orientation
HIF-1 Forward 5’-CACCT
Reverse 5’-GGCT
HIF-2 Forward 5’-CCTTC
Reverse 5’-TTCAT
CA9 Forward 5’-GCTG
Reverse 5’-CCAG
BNIP-3 Forward 5’-GATAT
Reverse 5’-CGCT
GLUT-1 Forward 5’-TGGC
Reverse 5’-CCAG
VEGF Forward 5’-CTTGC
Reverse 5’-CTGC
PHD-1 Forward 5’-CAGC
Reverse 5’-CAGAG
PHD-2 Forward 5’-GCAC
Reverse 5’-CCAG
PHD-3 Forward 5’-TTGG
Reverse 5’-CGTG
FIH-1 Forward 5’-CAATG
Reverse 5’-GGCC
18S RNA Forward 5’-GTAAC
Reverse 5’-CCATC
BNIP-3, BCL2/adenovirus E1B 19-kDa protein-interacting protein-3; C
transporter-1; HIF, hypoxia-inducible factor; PHD, prolyl-hydroxylase doms
Sequence Product size (bp)
CTGGACTTGCCTTTC-3’ 194
GCATCTCGAGACTTTT-3’
AAGACAAGGTCTGCA-3’ 190
CCGTTTCCACATCAA-3’
TCACCAGCGTCGCGT(T)-3 100
TCTCGGCTACCTCTGCT-3’
GGGATTGGTCAAGTCGG-3’ 101
CGTGTTCCTCATGCT-3’
ATGGCGGGTTGT-3’ 63
GGTAGCTGCTCCAGC-3’
CTTGCTGCTCTACCT-3’ 282
ATGGTGATGTTGGACT-3’
TAGCATCAGGACAGAAA-3’ 174
GCAAAGTCAGAAGCA-3’
GACACCGGGAAGTT-3’ 178
CTTCCCGTTACAGT-3’
GATGCCAAGCTACA-3’ 125
TGGGTTCCTACGATCT-3’
TACTGGTGGCATCACATAG-3’ 131
ACTTTCTGATGAGCTT-3’
CCGTTGAACCCCA-3’ 152
CAATCGGTAGTAGCG-3’
A9, carbonic anhydrase-9; FIH-1, factor-inhibiting HIF-1; GLUT-1, glucose
